Electra Therapeutics is a clinical-stage biotechnology company focused on SIRP-targeted therapies, specifically its lead candidates ipsoprubart and ELA822. As of November 2026, the company remains pre-revenue with significant operating losses and expects to require substantial additional capital to fund its research and development programs.
Electra Therapeutics reported third quarter 2026 financial results and provided updates on its SIRP-targeting portfolio, including the advancement of ipsoprubart in a global registrational program for sHLH. The company recently completed a $350 million IPO to fund its clinical pipeline, with several data readouts and enrollment milestones expected throughout 2027.
“Our recent IPO positions Electra to build on our first-mover advantage in SIRP-targeted precision immune cell depletion. Our deep expertise in SIRP biology and proprietary library of SIRP-targeting antibodies enable us to selectively address distinct pathogenic immune cell populations, creating therapeutic optionality across immune-mediated diseases and cancer.”
Kathy Dong, PharmD, MBA, President and Chief Executive Officer
Electra Therapeutics Insider Carl L. Gordon Buys $745K of Stock
Carl L. Gordon bought 92,116 shares of Electra Therapeutics, Inc. at $7.85 to $8.45 a share (average $8.08) in 6 transactions, worth $745K in total between Nov 6, 2026 and Nov 10, 2026. Shares held after the trade: 2,194,579 (+0.1%).
Electra Therapeutics Insider Orbimed Advisors LLC Buys $745K of Stock
Orbimed Advisors LLC bought 92,116 shares of Electra Therapeutics, Inc. at $7.85 to $8.45 a share (average $8.08) in 6 transactions, worth $745K in total between Nov 6, 2026 and Nov 10, 2026. Shares held after the trade: 2,194,579 (+0.1%).
Electra Therapeutics Insider Carl L. Gordon Buys $3.61M of Stock
Carl L. Gordon bought 472,571 shares of Electra Therapeutics, Inc. at $7.07 to $7.88 a share (average $7.63) in 10 transactions, worth $3.61M in total between Nov 3, 2026 and Nov 5, 2026. Shares held after the trade: 2,136,979 (+6.2%).
Electra Therapeutics Insider Orbimed Advisors LLC Buys $3.61M of Stock
Orbimed Advisors LLC bought 472,571 shares of Electra Therapeutics, Inc. at $7.07 to $7.88 a share (average $7.63) in 10 transactions, worth $3.61M in total between Nov 3, 2026 and Nov 5, 2026. Shares held after the trade: 2,136,979 (+6.2%).